Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination, covering 2019-08-16 to 2019-08-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 [Phase 3]